Keyword: Hikma Pharmaceuticals
Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.
The FDA is reporting shortages of anesthetics used to treat COVID-19 patients as the novel coronavirus pandemic continues to strain the supply chain.
Hikma has stopped production of an injected pain drug as it figures out how to fix an issue that has resulted in black, oily particles in vials.
Rising Pharmaceuticals pleads to price fixing, and a pilot-scale lyophilization facility is being made available for pilot projects.
Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.
Here is some news of note for the week.
Here are some of the other stories we're following today.
Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.
Hikma, which has established itself as a top sterile injectables manufacturer in the U.S., is now picking up a production plant in Vietnam.
Acorda faces the prospect of generic competition on its primary revenue source, Ampyra, after an appeals court's decision.